Stock Price Quote

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE973.65-4.65 (-0.48 %)
PREV CLOSE ( ) 978.30
OPEN PRICE ( ) 975.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16630
TODAY'S LOW / HIGH ( )965.00 978.30
52 WK LOW / HIGH ( )797.05 1323.9
NSE972.95-5.5 (-0.56 %)
PREV CLOSE( ) 978.45
OPEN PRICE ( ) 978.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 972.95 (400)
VOLUME 721738
TODAY'S LOW / HIGH( ) 965.00 980.85
52 WK LOW / HIGH ( )795 1324.3
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-05 1995
Management Info
Pankaj R Patel - Chairman Sharvil P Patel - Managing Director
Registered Office

Address Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway,
Ahmedabad,
Gujarat-382481

Phone 079-71800000 / 48040000

Email dhavalsoni@zyduscadila.com

Website www.zyduscadila.com

Registrars Details
MUFG Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

03Jul Zydus Lifesciences informs about newsp
Zydus Lifesciences has informed that it enclosed the newspaper cutting d..
19Jun USFDA concludes GMP follow-up inspecti
US Food and Drug Administration (USFDA) has concluded GMP follow-up insp..
19Jun Zydus Lifesciences informs about inve
Zydus Lifesciences has informed that the management of the Company will..
19Jun Announcement under Regulation 30 (LOD
Closure of USFDA inspection at Zydus'' oncology injectable plant at Ahme..
12Jun Zydus Lifesciences gets EIR for Ankles
Zydus Lifesciences has received the Establishment Inspection Report (EIR..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit2813757749
Gross Profit 36747 74447
Operating Profit 3958184325
Net Sales 58196151163

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  34611.10 (0.76%)
M.Cap ( in Cr)73546.17
Glenmark Pharma (BSE)
peergroup  1905.15 (4.80%)
M.Cap ( in Cr)53763.49
NGL Fine-Chem (BSE)
peergroup  1325.00 (4.33%)
M.Cap ( in Cr)818.59
Emcure Pharma (BSE)
peergroup  1283.55 (2.18%)
M.Cap ( in Cr)24324.34
Kwality Pharma (BSE)
peergroup  1167.55 (2.08%)
M.Cap ( in Cr)1211.47

Shareholding Pattern

PROMOTERS 74.99%
NON-INSTITUTION 6.68%
MUTUAL FUNDS/UTI 6.36%
FI/BANKS/INSURANCE 4.4%
GOVERNMENT 0%
FII 0%

About Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd. was incorporated in the year 1995. Its today's share price is 973.65. Its current market capitalisation stands at Rs 97971.97 Cr. In the latest quarter, company has reported Gross Sales of Rs. 108252 Cr and Total Income of Rs.119816 Cr. The company's management includes Shelina P Parikh, Dhaval N Soni, Ganesh N Nayak, Sharvil P Patel, Mukesh M Patel, Upasana Konidela, Akhil Monappa, Apurva S Diwanji, Bhadresh K Shah, Pankaj R Patel.

It is listed on the BSE with a BSE Code of 532321 , NSE with an NSE Symbol of ZYDUSLIFE and ISIN of INE010B01027. It's Registered office is at Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar HighwayAhmedabad-382481, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Mukesh M Shah & Co, RR Patel & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.